Dexamethasone reduces tumor recurrence and metastasis after pancreatic tumor resection in SCID mice
Related Experiment Video
Updated: Jul 5, 2026
An Orthotopic Resectional Mouse Model of Pancreatic Cancer
Published on: September 24, 2020
Jan-Hendrik Egberts1, Bodo Schniewind, Miriam Pätzold
1Division of Molecular Oncology, Department of General Surgery and Thoracic Surgery, University Hospital of Schleswig-Holstein, Kiel, Germany.
Background:
Glucocorticoids are among the most potent anti-inflammatory agents that act by inhibiting the synthesis of almost all known cytokines and influencing multiple transduction pathways. Inflammation accompanies most solid cancers including pancreatic ductal adenocarcinoma (PDAC), one of the most fatal cancers with surgery being the only potential curative therapeutic. In the present work we investigated the influence of glucocorticoids on PDAC cells in vitro as well as in vivo in a pancreatic carcinoma resection mouse model.
Methods:
The influence of dexamethasone (DEX), a synthetic glucocorticoid, on proliferation and IL8 secretion in pancreatic cells (BxPC3, Colo357, PancTuI) was analyzed by cell counting and ELISA. NFkappaB-activity of PancTuI cells treated with DEX was determined by electrophoretic mobility shift assay (EMSA). Furthermore, effects of DEX on the invasiveness were studied by a fibroblast-based invasion assay. In the mouse resection model subtotal pancreatectomy was performed after orthotopic inoculation of human PDAC cells. DEX was administered after resection as an adjuvant treatment regime and 4 weeks later, local recurrent tumor sizes as well as number of liver and spleen metastases were analyzed.
Results:
In vitro, DEX did not have an anti-proliferative effect on PDAC cells, but strongly reduced the invasiveness well as the activation of NFkappaB. The secretion of IL-8 into the supernatant of the tumor cells correlated inversely with the reduced activation of NFkappaB. In vivo, we observed a significant reduction of the local recurrent tumor volume and the number of liver and spleen metastases.
Conclusions:
DEX has a profound influence on the malignant phenotype of PDAC tumor cells in vitro in terms of inhibition of invasiveness and pro-inflammatory signaling. This was approved in vivo by reduced metastasizing capacity and reduced size of local tumor recurrence. Therefore, DEX-treatment appears to be an interesting therapeutical option in an adjuvant setting after pancreatic cancer resection.
Insights
Dexamethasone (DEX) reduces pancreatic cancer cell invasiveness and inflammation. In mouse models, DEX treatment after surgery significantly decreased tumor recurrence and metastasis, suggesting its potential as an adjuvant therapy.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- Pancreatic ductal adenocarcinoma (PDAC) is a fatal cancer often accompanied by inflammation.
- Glucocorticoids are potent anti-inflammatory agents with broad effects on cellular signaling pathways.
- The role of glucocorticoids in PDAC progression and treatment remains to be fully elucidated.
Purpose of the Study:
- To investigate the effects of dexamethasone (DEX), a synthetic glucocorticoid, on pancreatic cancer cells.
- To evaluate DEX as an adjuvant therapy in a preclinical model of pancreatic cancer resection.
Main Methods:
- In vitro analysis of DEX effects on PDAC cell proliferation, IL-8 secretion, NF-kappaB activity, and invasiveness.
- In vivo study using a mouse model of PDAC with adjuvant DEX treatment post-surgery.
Main Results:
- DEX significantly reduced PDAC cell invasiveness and NF-kappaB activation in vitro.
- IL-8 secretion inversely correlated with NF-kappaB activity.
- In vivo, DEX treatment led to reduced local tumor recurrence and fewer liver/spleen metastases.
Conclusions:
- DEX profoundly impacts the malignant phenotype of PDAC cells by inhibiting invasiveness and pro-inflammatory signaling.
- Adjuvant DEX treatment demonstrated efficacy in reducing tumor recurrence and metastasis in a preclinical model.
- DEX shows promise as a therapeutic option in the adjuvant setting after pancreatic cancer surgery.
